Project Grant R01CA307404
- Federal Grant Award Summary The National Cancer Institute awarded the University of Michigan $682,272 under the Cancer Cause and Prevention Research program (CFDA 93.393) on September 1, 2025, for a two-year project (completion date August 31, 2027) to assess the feasibility and acceptability of a multifaceted electronic health record (EHR)-integrated mobile health intervention designed to reduce post-operative readmissions following radical cystectomy. The intervention consists of an...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $293,430 to the University of Michigan's Office of Research and Sponsored Projects on June 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to support a five-year research initiative examining regional cancer care delivery optimization. The project, led by a colorectal surgeon and health services researcher, will leverage Michigan's Collaborative Quality Initiatives (CQIs) as a learning laboratory to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $669,278 to the University of Michigan's Office of Research and Sponsored Projects, effective June 1, 2026 through May 31, 2031, under the Cancer Treatment Research program (CFDA 93.395). This Multi-Principal Investigator (MPI) R01 application, aligned with PAR-25-107 (Advancing Microbial-Based Cancer Therapy), supports the development of engineered nonpathogenic tumor-tropic E. coli bacteria...
- Federal Grant Award Summary The University of Michigan, through its Office of Research and Sponsored Projects, received a $610,498 Project Grant award from the National Cancer Institute under the Cancer Research Manpower program (CFDA 93.398) on August 1, 2025, with a completion date of July 31, 2030. This award funds a comprehensive training initiative designed to build nationwide investigator capacity in adaptive intervention methodology for cancer control. The project will deliver didactic...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant of $136,412 to the Regents of the University of Michigan, effective August 1, 2025 through July 31, 2027, under the Cancer Research Manpower program (CFDA 93.398). This award funds research aimed at defining and interrupting metabolic crosstalk in the glioblastoma microenvironment. The research builds upon preliminary findings demonstrating that glioblastoma (GBM) tumors acquire nutrients through...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan a $646,881 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026 through March 31, 2031. The research focuses on developing first-in-class small molecule inhibitors targeting ASH1L (Absent, Small or Homeotic 1-Like), a histone methyltransferase protein implicated in acute leukemia pathogenesis. The project addresses the urgent...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded the University of Michigan $660,808 under the Cancer Biology Research program (CFDA 93.396) on April 7, 2026, to investigate the durability and functionality of tissue-resident memory T cells (TRM) in melanoma treatment response and recurrence prevention. The research will examine how TRM cells with high interferon-gamma expression (TRM-IFNG) established at primary melanoma diagnosis are recalled and expanded to...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan $175,448 under the Cancer Research Manpower program (CFDA 93.398) on January 16, 2026, with completion targeted for July 31, 2027. This project grant supports research training and investigator development in cancer biology, specifically focused on characterizing cancer-associated fibroblasts (CAFs) and their role in pancreatic ductal adenocarcinoma (PDAC). The research aims to...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $165,080 to the Regents of the University of Michigan under the Cancer Research Manpower program (CFDA 93.398) to examine surveillance patterns and unmet needs among young colorectal cancer (CRC) survivors. The award, effective February 4, 2026, with an ultimate completion date of August 31, 2027, funds a mixed-methods research initiative that combines population-based quantitative analysis with qualitative patient...
- Federal Grant Award Summary The National Cancer Institute awarded the Regents of the University of Michigan a Project Grant of $401,115 under the Cancer Treatment Research program (CFDA 93.395) for the period July 1, 2026 through June 30, 2028. This research initiative focuses on developing novel therapeutic strategies targeting the enhancer landscape in high-risk T-cell lymphomas (TCL), particularly those driven by the transcription factor GATA-3, which currently represent an area of...
Grant Award Summary The National Cancer Institute (NCI) awarded the Regents of the University of Michigan a $490,836 Project Grant under the Cancer Cause and Prevention Research program (CFDA 93.393) on June 19, 2026, with a project completion date of May 31, 2031. This research initiative addresses the clinical management transition from active surveillance to observation in prostate cancer among older men (age 65+) with limited life expectancy. The project will examine patient factors associated with disease transitions, investigate clinician decision-making drivers regarding the shift from routine monitoring protocols (including prostate-specific antigen testing, magnetic resonance imaging scans, and periodic biopsies) to observation-based management, and evaluate long-term outcomes including disease progression, treatment decisions, and associated healthcare costs. The research responds to a significant clinical gap: while guidelines recommend transitioning men with comorbidities and limited life expectancy from active surveillance to observation to avoid overtreatment and unnecessary adverse effects, large-scale implementation patterns and outcomes remain largely unknown across the U.S. population of over 500,000 men currently managed with active surveillance. By characterizing these clinical transitions and their consequences, this project will generate evidence to inform guideline development and optimize prostate cancer management strategies for aging populations with concurrent medical conditions.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $490.8k | 6/23/26 |